RNTX – rein therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Rein Therapeutics (NASDAQ:RNTX) was given a new $6.00 price target on by analysts at Loop Capital.
Rein Therapeutics (NASDAQ:RNTX) was upgraded by analysts at Brookline Capital Management to a "buy" rating.
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Form 4 Rein Therapeutics, Inc. For: Nov 14 Filed by: Cocke Travis W.
Form 10-Q Rein Therapeutics, Inc. For: Sep 30
Form 8-K Rein Therapeutics, Inc. For: Nov 03
Form 4 Rein Therapeutics, Inc. For: Oct 24 Filed by: Cocke Travis W.
Form 8-K Rein Therapeutics, Inc. For: Oct 23
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.